METHOD FOR PROSTATE CANCER DIFFERENTIAL DIAGNOSIS BASED ON PLASMA MICRORNAS ANALYSIS Russian patent published in 2017 - IPC G01N33/574 C12Q1/68 

FIELD: medicine.

SUBSTANCE: hsa-miR-619-5p and hsa-miR-1184 microRNAs expression in the patient's blood plasma is measured by microarray analysis. At hsa-miR-619-5p microRNAs expression log2-scale more than 1.25 and hsa-miR-1184 microRNAs expression more than 3.5, prostate cancer is diagnosed. At hsa-miR-619-5p microRNAs expression log2-scale less than 1.25 and hsa-miR-1184 microRNAs expression less than 3.5, benign prostatic hyperplasia is diagnosed.

EFFECT: obtaining of new diagnostic marker for prostate cancer and benign prostatic hyperplasia, allowing to perform a differential diagnosis of prostate cancer and benign prostatic hyperplasia at comparable accuracy and specificity.

3 tbl, 6 ex